The case for cardiac troponin T: marker for effective risk stratification of patients with acute cardiac ischemia
| Autor: | Robert H. Christenson, Gladys L. Alonsozana |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
medicine.medical_specialty
Cardiac troponin biology business.industry Cardiac ischemia medicine.medical_treatment Biochemistry (medical) Clinical Biochemistry Disease medicine.disease Revascularization Troponin Surgery Troponin complex Internal medicine Risk stratification medicine Cardiology biology.protein cardiovascular diseases Myocardial infarction business |
| Zdroj: | Clinical Chemistry. 42:803-808 |
| ISSN: | 1530-8561 0009-9147 |
| DOI: | 10.1093/clinchem/42.5.803 |
| Popis: | Availability of markers such as cardiac troponin T (cTnT) has brought new insights into ischemic heart disease (IHD). cTnT is a distinct protein that differs from other markers in biological function, molecular mass, and cytosolic pool. cTnT has been utilized for diagnosis of acute myocardial infarction (AMI) and risk stratification of patients with IHD. For AMI diagnosis, cTnT showed high sensitivity (94-100%) but generally lower specificity (46-99%), possibly because of increases in non-AMI patients with minor myocardial damage. Outcome studies have demonstrated that IHD patients with increased cTnT are at significantly greater risk for cardiac events; revascularization in patients with increased cTnT may improve outcome. Estimated costs for batched ES 300 cTnT results and for a cTnT rapid assay run "on demand" were $17.48 and $21.65, respectively. cTnT currently has no specific common procedure test code; expected reimbursement is $18.32 for the ES 300 and is not established for the rapid assay. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|